tECHNOLOGY & iNNOVATION: #BenchMark-BrainRecovery

THE PROBLEM AND THE IMPORTANCE

     Too many suffer alone, whether it is Grandma Mary, Aunt Shelly, Uncle Bob, or your mom. Alone meaning patients must travel far away from their homes for treatment, as a local care does not exist. Alone meaning no one can hear their cries because of their brain condition. Alone meaning treatment is not working.

     All the above, plus the costs in treatments is always expensive. The Alzheimer’s drug Aduhelm costs $56,000 per year. The European Union rejected the drug because it did not work after reviewing clinical trial results. Surprisingly, the FDA approved even after the FDA’s own review committee rejected it. Lucky for veterans and others depended on veterans and state hospitals, they are not using that defective drug. Sadly for them, nothing is working, even at the super-expensive prices.

     As the result of the above, the CDC predicts by 2040 the cost to treat Alzheimer’s Disease will be $379 billion to $500 billion annually. Along these lines, “Grandma Bernita” informed us a relative in Texas was diagnosed with Alzheimer’s, and before we could say anything, grandma said, “nothing can be done because with ‘Aunt Mary’, it is hereditary.” This is how too many feel. And this is just on Alzheimer's Disease, as other brain diseases are also unsolved.

PROJECT [24-month] EXPECTED IMPACT: #BenchMark-BrainRecovery

     No specialty healthcare facility is required for this project; any clinic to include rural clinics or clinics on Native American Reservations can apply it to their patients = easily scalable.

     What? By providing ways to help normal adaptive physiology of the human body for adult patients.

     How? Using diverse FDA-cleared medical equipment [drugs = FDA-approved; medical equipment = FDA-cleared] that does not require years or training.

     In addition, patients do not have to do anything at home. Why is this a big deal? Patient non-compliance in the U.S. is a problem, as 75% of Americans have trouble following their doctor’s/medication’s instructions.     

WHY NOT DONE BEFORE

     Never done are projects using FDA-cleared medical equipment from different vendors because they make no money for the organization conducting the study. Another reason no organization wants to do this is no patents are created, consequently not a revenue-generating project.

     Another of our competitive advantages? Selling patient data is  another common source of revenue for too many organizations. We do not do this, but here are two high-profile examples on the behind-the-scenes of selling patient data:

• A consortium of over 280 clinical trial doctors calling themselves “The International Consortium of Investigators for Fairness in Trial Data Sharing” demanded ownership of ALL patients’ data = “…it is deeply upsetting that there are more than 280 researchers who are more concerned about their own careers than the lives of the patients on whom those careers are built. Bettina Ryll, M.D., Ph.D., Melanoma Patient Network Europe [New England Journal of Medicine].
• The Alzheimer’s Disease Cooperative Study was not cooperative. University of California-San Diego and University of Southern California fought a nasty battle in court on who would have total control of the patient data because this is a huge financial windfall for the university.

Adults suffering from brain issues like Alzheimer's Disease, regardless of location [many funders discriminate based on organization location], race [most of these kinds of project use only white people], gender [most of these projects use males [FYI: even the "female viagra" test population was 70% male before it became a commercially-available product], etc. all in an effort to skew data for commercial purposes. As anyone knows, this is old new on the discrimination parts. We do none of the above "statiscally selective" processes.

This is not a typical hospital-academic expensive process, nor we have an extensive publication record because we are not in academia where massive publications is the cornerstone of that industry. The team is part of a small clinic, and the primary doc with a DEA license has been in that location for decades [moved his office from NJ and Manhattan, NY]. Our process is a strong HIPPA-compliant process, as even if systems are stolen no one can do anything with that information because they systems are coded and the encryption sheet is not within any of the systems. There is also experience with these kinds of processes involved with AIDS patients for example. As such, we have develop a priority patient questionnaire for before/after assessment that will be made public once this process is completed for others to follow or modify to suit their patients.

Not implemented yet, but we have the information & instruments needed to move forward. It starts with quality, then can easily expand [because of the small clinic approach] for others to follow. This makes it scalable to a national level as well as a global level.

Initial one-time financials (monetary support) [FYI: none to overhead] from one funder or six.

As noted earlier, this combines FDA-cleared instruments. This has not done before. This low-risk/high-reward process. Also noted earlier, this approach is focused on the small clinics not the typical large hospital or specialty clinics where people have difficulty accessing because of location or cost. This will changes the market in the healthcare space, to include with patient compliance also noted ealier...we just need that opportunity to show this will work within our 24-month project. 

Within 24 months complete the healthcare process to have it expand nationally with a primary focus on rural clinics, transforming people's lives regardless of age segmentations [FYI: insurance company = "this drug we are not covering for you anymore because are actuarial models show you are not worth saving because of your age."] and gender, for two examples.

Also as noted before with our before/after assessment process we will make public. In addition, scans and balances also using FDA-instruments, and filming.

THEORY OF CHANGE for the low risk/high-reward #BenchMark-BrainRecovery = By providing ways to help normal adaptive physiology of the human body for adult patients.

A core of different FDA-cleared instruments. The details will be noted globally once completed the 24-month process. This involves both software and hardware.

As noted earlier, we do not discriminate based on age, gender, location, etc. as it is typical for these types of projects. Women + Hispanic = 80%.

Key customers are those who go to small clinics and who run small clinics, whether independent or Country/State-runned clinics. In short, that is our Beachhead customers. All without increasing staff, another competitive advantage from the others we noted earlier. Why the need it? As noted earlier in just one brain disease, "...the CDC predicts by 2040 the cost to treat Alzheimer’s Disease will be $379 billion to $500 billion annually."

After the initial one-time funding, the process will be self-financially reliant, as small clinics remain small. Increasing the size of small clinics is financially unwarranted. This is our core model as it is realistic. This is based on

Berkus Method for the initial years, the Risk Factor Summation Method in midyears, and Venture Capital Method in the latter years.

     No funders yet, beginning this process. Our current approach:

     In your eyes, we don’t have a past to anchor to. So naturally, we want you to think then of our future partnership. This kind of reverse chronology, the future partnership, fosters the kind of unconstrained thinking leading to this low-risk, high-impact program stated in the proposal. After we publish our lessons-learned report [really, our program results], this program no doubt will then propel other non-profits to adapt for their non-profit’s mission with a much shorter program development time.

    We view future partnerships as school dances. During school dances, students wait for someone to get on the dance floor before they jump in to dance as well. Once that first person jumps in, invariably most jump in thereafter. Being the first is always frightful, especially when there is no past to anchor to.

     Granted, reverse chronology is not foolproof, but a future-focused mindset will continue to be an important driver in programs having true impacts not just temporary ones to fulfill funders’ paperwork requirements. Therefore, our ultimate program goal is to help people, households, and communities to help themselves, and this unique program will help achieve this goal. This durability approach to development challenges rarely involves one player implementing a quick fix, even if that is a technology one. This is where your organization comes into play. While mega-corporations use their advantages to raise funds for their future programs, we do the same but through grants. So, this is why we want you to be first on that dance floor, then others can follow your lead on this low-risk, high reward program.